In an advance toward closing a major gap in defenses against terrorist attacks and other mass casualty events, scientists are reporting discovery of a promising substance that could be the basis for development of a better antidote for cyanide poisoning. Their report, which describes a potential antidote that could be self-administered, much like the medication delivered by allergy injection pens, appears in ACS' Journal of Medicinal Chemistry.
Steven E. Patterson, Ph.D., and colleagues at the University of Minnesota Center for Drug Design explain that the only existing antidotes for cyanide — recognized as a high-risk substance for potential use by terrorists — must be administered by intravenous infusion. That procedure requires highly trained paramedical personnel and takes time. Cyanide, however, is a fast-acting poison. In a situation involving mass casualties, only a limited number of victims could be saved. Patterson's team thus sought an antidote that could be administered by intra-muscular (IM) injection, a simpler procedure that could be administered rapidly to a large number of victims or even be self-administered.
Their report describes discovery of a substance, sulfanegen TEA, "which should be amenable for development as an IM injectable antidote suitable for treatment of cyanide victims in a mass casualty setting. Further development, including efficacy in lethal cyanide animal models, will be reported at a later date."
The authors acknowledge financial support from the National Institutes of Health through the National Institute of Neurological Disorders and Stroke (award #UO1NS058087-05).
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 163,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com.
Follow us: Twitter Facebook
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.